FDA approves first medication for obstructive sleep apnea, promotes weight loss
The U.S. Food and Drug Administration (FDA) recently approved the first medication for obstructive sleep apnea, a condition that affects millions of people in the United States. Eli Lilly’s Zepbound (tirzepatide) has been given the green light to treat moderate to severe obstructive sleep apnea in adults with obesity. This groundbreaking approval marks a major milestone in the treatment of this common sleep disorder.
Obstructive sleep apnea occurs when the upper airway becomes blocked during sleep, leading to pauses in breathing. This condition is more prevalent in individuals who are overweight or obese. Zepbound works by activating receptors of hormones secreted from the intestine to reduce appetite and food intake, similar to other treatments like Ozempic and Wegovy. By reducing body weight, Zepbound has been shown to improve obstructive sleep apnea in patients.
In a 52-week study, participants treated with Zepbound experienced a significant reduction in apnea or hypopnea events, with many achieving remission or resolution of symptoms. Patients also reported a decrease in body weight while taking the medication. However, Zepbound may cause side effects such as nausea, diarrhea, vomiting, constipation, and fatigue, among others. It is important for patients to consult with a doctor before starting treatment and to monitor for any complications.
While Zepbound has shown promising results in treating obstructive sleep apnea, it is not suitable for individuals with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. The FDA advises caution and close monitoring for all patients using Zepbound.
Sleep expert Dr. Wendy Troxel has hailed the FDA’s approval of Zepbound as a significant advancement for individuals suffering from obstructive sleep apnea. She emphasized the importance of treating this condition, not only for the patient’s health but also for their bed partners who may be affected by loud snoring and gasping for air.
Dr. William Lu, medical director of Dreem Health, praised the new medication as a potential game-changer for individuals with obesity and sleep apnea. He stressed the importance of lifestyle changes in conjunction with medication to improve overall health outcomes.
In conclusion, the approval of Zepbound by the FDA represents a major breakthrough in the treatment of obstructive sleep apnea. This medication offers a new option for patients who may struggle with traditional therapies and provides hope for improved quality of life for those affected by this common sleep disorder. It is essential for individuals to undergo testing for sleep apnea and consult with a healthcare provider before starting any new treatment regimen.
